Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

This study is testing epcoritamab — a new type of targeted antibody treatment given as an injection under the skin — for patients with follicular lymphoma (a slow-growing B-cell lymphoma) who did not achieve a complete remission after their initial chemo-immunotherapy treatment. **You may be eligible if...** - You have biopsy-confirmed follicular lymphoma (grade 1–3A) that is CD20-positive - Your lymphoma is Stage III or IV - You have received at least 3 cycles of upfront (first-line) treatment that included rituximab plus chemotherapy - You did not achieve a complete remission (CR) after this first-line treatment - You have at least one measurable tumor on PET/CT scan **You may NOT be eligible if...** - Your follicular lymphoma has transformed into a more aggressive type (high-grade) - You have received more than one prior line of systemic therapy - You have active central nervous system lymphoma - You have a serious active infection or other major medical condition Talk to your doctor to see if this trial is right for you.